Spotlight on brodalumab in the treatment of plaque psoriasis: the evidence to date

References

• World Health Organization. Global Report on Psoriasis. Geneva: World Health Organization; 2016.
   Google Scholar
• Strohal R, Kirby B, Puig L, et al. Psoriasis beyond the skin: an expert group consensus on the management of psoriatic arthritis and common co-morbidities in patients with moderate-to-severe-psoriasis. J Eur Acad Dermatol Venereol. 2014;28(12):1661–1669. doi:10.1111/jdv.2014.28.issue-1224372845
   PubMed Web of Science ®Google Scholar
• Talamonti M, Galluzzo M, Servoli S, D’Adamio S, Bianchi L. Alexithymia and plaque psoriasis: preliminary investigation in a clinical sample of 250 patients. Dermatology. 2016;232(6):648–654. doi:10.1159/00045366128152541
   PubMed Web of Science ®Google Scholar
• Oliveira Mde F, Rocha Bde O, Duarte GV. Psoriasis: classical and emerging comorbidities. An Bras Dermatol. 2015;90(1):9–20. doi:10.1590/abd1806-4841.2015303825672294
   PubMed Web of Science ®Google Scholar
• American Academy of Dermatology Work Group; Menter A, Korman NJ, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 6. Guidelines of care for the treatment of psoriasis and psoriatic arthritis: case-based presentations and evidence-based conclusions. J Am Acad Dermatol. 2011;65(1):137–174. doi:10.1016/j.jaad.2010.11.05521306785
   PubMed Web of Science ®Google Scholar
• Griffiths CE, Barker JN. Pathogenesis and clinical features of psoriasis. Lancet. 2007;370(9583):263–271. doi:10.1016/S0140-6736(07)61128-317658397
   PubMed Web of Science ®Google Scholar
• Warren RB. Efficacy and safety of emerging immunotherapies in psoriasis. Immunotherapy. 2015;7(2):119–133. doi:10.2217/imt.14.10125713988
   PubMed Web of Science ®Google Scholar
• Schadler ED, Ortel B, Mehlis SL. Biologics for the primary care physician: review and treatment of psoriasis. Dis Mon. 2019;65(3):51–90.30037762
   PubMed Web of Science ®Google Scholar
• Lowes MA, Kikuchi T, Fuentes-Duculan J, et al. Psoriasis vulgaris lesions contain discrete populations of Th1 and Th17 T cells. J Investig Dermatol. 2008;128(5):1207–1211. doi:10.1038/sj.jid.570121318200064
   PubMed Web of Science ®Google Scholar
• Marinoni B, Ceribelli A, Massarotti MS, Selmi C. The Th17 axis in psoriatic disease: pathogenetic and therapeutic implications. Auto Immun Highlights. 2014;5(1):9–19. doi:10.1007/s13317-013-0057-426000152
   PubMedGoogle Scholar
• Chang SH, Dong C. A novel heterodimeric cytokine consisting of IL-17 and IL-17F regulates inflammatory responses. Cell Res. 2007;17:435–440. doi:10.1038/cr.2007.3517452998
   PubMed Web of Science ®Google Scholar
• Carrascosa JM, Jacobs I, Petersel D, Strohal R. Biosimilar drugs for psoriasis: principles, present, and near future. Dermatol Ther (Heidelb). 2018;8(2):173–194. doi:10.1007/s13555-018-0230-929549597
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Summary of Product Characteristics: Kyntheum 210 mg Solution for Injection in Pre-Filled Syringe; 2017 Available from: http://www.ema.europa.eu. Accessed 227, 2018.
   Google Scholar
• Papp KA, Reich K, Paul C, et al. A prospective phase 3, randomized, double-blind, placebo-controlled study of brodalumab in patients with moderate-to severe plaque psoriasis. Br J Dermatol. 2016;175(2):273–286. doi:10.1111/bjd.1449326914406
   PubMed Web of Science ®Google Scholar
• Armstrong A, Blauvelt A, Wu JJ et al. Retreatment with brodalumab results in high response rates in patients with psoriasis after treatment interruption. Abstract from 76th Annual Meeting of the American Academy of Dermatology; 2 16–20; 2018; San Diego, CA.
   Google Scholar
• Masson Regnault M, Konstantinou MP, Khemis A, et al. Early relapse of psoriasis after stopping brodalumab: a retrospective cohort study in 77 patients. J Eur Acad Dermatol Venereol. 2017;31(9):1491–1496. doi:10.1111/jdv.1438728585707
   PubMed Web of Science ®Google Scholar
• Philipp S, Hansen JB, Schultz Nielsen V et al. Long-term efficacy of brodalumab for the treatment of moderateto-severe psoriasis in two pivotal phase 3 clinical trials. Abstract from 27th EADV Congress; 9 12–16; 2018; Paris, France.
   Google Scholar
• Lebwohl M, Strober B, Menter A, et al. Phase 3 studies comparing brodalumab with ustekinumab in psoriasis. N Engl J Med. 2015;373(14):1318–1328. doi:10.1056/NEJMoa150382426422722
   PubMed Web of Science ®Google Scholar
• Lebwohl M, Papp KA, Tyring S et al. Long-term efficacy of brodalumab for the treatment of moderate-to-severe psoriasis in two pivotal phase 3 clinical trials. Abstract from 27th EADV Congress; 9 12–16; 2018; Paris, France.
   Google Scholar
• Papp K, Leonardi C, Menter A, et al. Safety and efficacy of brodalumab for psoriasis after 120 weeks of treatment. J Am Acad Dermatol. 2014;71(6):1183–1190.e3. doi:10.1016/j.jaad.2014.08.03925313095
   PubMed Web of Science ®Google Scholar
• Lambert J, Hansen BJ, Nielsen V et al. Correlation between psoriasis area and severity index and dermatology life quality index in patients with moderate to severe psoriasis treated with brodalumab in the AMAGINE studies. Abstract from 27th EADV Congress; 9 12–16; 2018; Paris, France.
   Google Scholar
• Blauvelt A, Papp KA, Lebwohl MG, et al. Rapid onset of action in patients with moderate-to-severe psoriasis treated with brodalumab: A pooled analysis of data from two phase 3 randomized clinical trials (AMAGINE-2 and AMAGINE-3). J Am Acad Dermatol. 2017;77(2):372–374. doi:10.1016/j.jaad.2017.03.02628711089
   PubMed Web of Science ®Google Scholar
• Griffiths CEM, Reich K, Lebwohl M, et al. Comparison of ixekizumab with etanercept or placebo in moderateto-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials. Lancet. 2015;386(9993):541–551. doi:10.1016/S0140-6736(15)60125-826072109
   PubMed Web of Science ®Google Scholar
• Langley RG, Elewski BE, Lebwohl M. Secukinumab in plaque psoriasis: results of two phase 3 trials. N Engl J Med. 2014;371(4):326–338. doi:10.1056/NEJMoa131425825007392
   PubMed Web of Science ®Google Scholar
• Leonardi C, Langley R, Blauvelt A, et al. Rapid onset of efficacy in patients with psoriasis treated with ixekizumab: a pooled analysis of data from two randomized clinical trials (UNCOVER-2 and UNCOVER-3). Poster Presented at Am Acad Dermatol Annual Meeting; 3; 2016; Washington, DC.
   Google Scholar
• Reich K, Nielsen V, Hansen JB et al. Achieving complete clearance in the AMAGINE-2 and -3 studies: complete clearance over time in patients with moderate to severe plaque psoriasis treated with brodalumab up to 52 weeks. Abstract from 27th EADV Congress; 9 12–16; 2018; Paris, France.
   Google Scholar
• Gottlieb AB, Gordon K, Hsu S, et al. Improvement in itch and other psoriasis symptoms with brodalumab in phase 3 randomized controlled trials. J Eur Acad Dermatol Venereol. 2018. doi:10.1111/jdv.14913
   Web of Science ®Google Scholar
• Papp KA, Leonardi C, Menter A, et al. Brodalumab, an anti-interleukin-17- receptor antibody for psoriasis. N Engl J Med. 2012;366(13):1181–1189. doi:10.1056/NEJMoa110901722455412
   PubMed Web of Science ®Google Scholar
• Pavelka K, Chon Y, Newmark R, Lin S-L, Baumgartner S, Erondu N. A study to evaluate the safety, tolerability, and efficacy of brodalumab in subjects with rheumatoid arthritis and an inadequate response to methotrexate. J Rheumatol. 2015;42(6):912–919. doi:10.3899/jrheum.14127125877498
   PubMed Web of Science ®Google Scholar
• Targan SR, Feagan B, Vermeire S, et al. A randomized, double-blind, placebo controlled phase 2 study of brodalumab in patients with moderate-to-severe Crohn’s disease. Am J Gastroenterol. 2016;111(11):1599–1607. doi:10.1038/ajg.2016.29827481309
   PubMed Web of Science ®Google Scholar
• Mease PJ, Genovese MC, Greenwald MW, et al. Brodalumab, an anti-IL17RA monoclonal antibody, in psoriatic arthritis. N Engl J Med. 2014;370(24):2295–2306. doi:10.1056/NEJMoa131523124918373
   PubMed Web of Science ®Google Scholar
• Nakagawa H, Niiro H, Ootaki K; Japanese Brodalumab Study Group. Brodalumab, a human anti-interleukin-17-receptor antibody in the treatment of Japanese patients with moderate-to-severe plaque psoriasis: efficacy and safety results from a phase II randomized controlled study. J Dermatol Sci. 2016;81(1):44–52. doi:10.1016/j.jdermsci.2015.10.00926547109
   PubMed Web of Science ®Google Scholar
• Busse WW, Holgate S, Kerwin E, et al. Randomized, double-blind, placebocontrolled study of brodalumab, a human anti-IL-17 receptor monoclonal antibody, in moderate to severe asthma. Am J Respir Crit Care Med. 2013;188(11):1294–1302. doi:10.1164/rccm.201212-2318OC24200404
   PubMed Web of Science ®Google Scholar
• Yamasaki K, Nakagawa H, Kubo Y, Ootaki K; Japanese Brodalumab Study Group. Efficacy and safety of brodalumab in patients with generalized pustular psoriasis and psoriatic erythroderma: results from a 52-week, open-label study. Br J Dermatol. 2017;176(3):741–751. doi:10.1111/bjd.1470227106510
   PubMed Web of Science ®Google Scholar
• Danesh MJ, Kimball AB. Brodalumab and suicidal ideation in the context of a recent economic crisis in the United States. J Am Acad Dermatol. 2016;74(1):190–192. doi:10.1016/j.jaad.2015.08.05726702804
   PubMed Web of Science ®Google Scholar
• Celgene Corporation. Highlights of Prescribing Information. Available from: http://www.otezla.com/otezla-prescribinginformation.pdf. Accessed 75, 2018.
   Google Scholar
• Galluzzo M, D’adamio S, Bianchi L, Talamonti M. Brodalumab for the treatment of psoriasis. Expert Rev Clin Immunol. 2016;12(12):1255–1271. doi:10.1080/1744666X.2016.124695727718760
   PubMed Web of Science ®Google Scholar
• Lebwohl MG, Papp KA, Marangell LB, et al. Psychiatric adverse events during treatment with brodalumab: analysis of psoriasis clinical trials. J Am Acad Dermatol. 2018;78(1):81–89.e5. doi:10.1016/j.jaad.2017.08.02428985956
   PubMed Web of Science ®Google Scholar
• Mundt JC, Greist JH, Gelenberg AJ, Katzelnick DJ, Jefferson JW, Modell JG. Feasibility and validation of a computer-automated Columbia-suicide severity rating scale using interactive voice response technology. J Psychiatr Res. 2010;44(16):1224–1228. doi:10.1016/j.jpsychires.2010.04.02520553851
   PubMed Web of Science ®Google Scholar
• Kroenke K, Strine TW, Spitzer RL, et al. The PHQ-8 as a measure of current depression in the general population. J Affect Disord. 2009;114(1–3):163–173. doi:10.1016/j.jad.2008.06.02618752852
   PubMed Web of Science ®Google Scholar
• Posner K, Oquendo MA, Gould M, Stanley B, Davies M. Columbia Classification Algorithm of Suicide Assessment (C-CASA): classification of suicidal events in the FDA’s pediatric suicidal risk. Am J Psychiatry. 2007;164:1035–1043. doi:10.1176/ajp.2007.164.7.103517606655
   PubMed Web of Science ®Google Scholar
• Chiricozzi A, Romanelli M, Saraceno R, Torres T. No meaningful association between suicidal behavior and the use of IL-17A-neutralizing or IL-17RA-blocking agents. Expert Opin Drug Saf. 2016;15(12):1653–1659. doi:10.1080/14740338.2016.122887227554637
   PubMed Web of Science ®Google Scholar
• Rieder EA. In response to Lebwohl et al, “Psychiatric adverse events during treatment with brodalumab: analysis of psoriasis clinical trials”. J Am Acad Dermatol. 2018;78(3):e73. doi:10.1016/j.jaad.2017.10.05229447687
   PubMed Web of Science ®Google Scholar
• Cohen BE, Martires KJ, Ho RS. Psoriasis and the risk of depression in the US population: national health and nutrition examination survey 2009–2012. JAMA Dermatol. 2016;152(1):73–79. doi:10.1001/jamadermatol.2015.360526421371
   PubMed Web of Science ®Google Scholar
• Liu Y, Ho RC, Mak A. The role of interleukin (IL)-17 in anxiety and depression of patients with rheumatoid arthritis. Int J Rheum Dis. 2012;15(2):183–187. doi:10.1111/j.1756-185X.2011.01673.x22462422
   PubMed Web of Science ®Google Scholar
• Kim JW, Kim YK, Hwang JA, et al. Plasma levels of IL-23 and IL-17 before and after antidepressant treatment in patients with major depressive disorder. Psychiatry Investig. 2013;10(3):294–299. doi:10.4306/pi.2013.10.3.294
   PubMed Web of Science ®Google Scholar
• Siliq (brodalumab) [package insert]. Bridgewater, NJ: Valeant Pharmaceuticals North America LLC; 2 2017.
   Google Scholar
• Rusta-Sallehy S, Gooderham M, Brodalumab: PK. A review of safety. Skin Therapy Lett. 2018;23(2):1–3.
   PubMedGoogle Scholar
• Munera-Campos M, Ballesca F, Richarz N, et al. Paradoxical eczematous reaction to ixekizumab. J Eur Acad Dermatol Venereol. 2018. doi:10.1111/jdv.15156
   PubMed Web of Science ®Google Scholar
• Burlando M, Cozzani E, Russo R, et al. Atopic-like dermatitis after Secukinumab injection: a case report. Dermatol Ther. 2018;20:e12751. doi:10.1111/dth.12751
   Web of Science ®Google Scholar
• Guttman-Yassky E, Brunner PM, Neumann AU, et al. Efficacy and safety of fezakinumab (an anti-IL-22 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by conventional treatments—a randomized, double-blind, phase 2a trial. J Am Acad Dermatol. 2018;78(872e81.e6). doi:10.1016/j.jaad.2018.01.016.
   Web of Science ®Google Scholar
• Guttman-Yassky E, Krueger JG. Atopic dermatitis and psoriasis: two different immune diseases or one spectrum? Curr Opin Immunol. 2017;48:68e73. doi:10.1016/j.coi.2017.08.00828869867
   PubMed Web of Science ®Google Scholar
• Esaki H, Brunner PM, Renert-Yuval Y, et al. Early onset pediatric atopic dermatitis is TH2 but also TH17 polarized in skin. J Allergy Clin Immunol. 2016;138:1639e51. doi:10.1016/j.jaci.2016.07.01327671162
   PubMed Web of Science ®Google Scholar
• Noda S, Suarez-Farinas M, Ungar B, et al. The Asian atopic dermatitis phenotype combines features of atopic dermatitis and psoriasis with increased TH17 polarization. J Allergy Clin Immunol. 2015;136:1254e64. doi:10.1016/j.jaci.2015.04.01026428954
   PubMed Web of Science ®Google Scholar
• Suarez-Farinas M, Dhingra N, Gittler J, et al. Intrinsic atopic dermatitis shows similar TH2 and higher TH17 immune activation compared with extrinsic atopic dermatitis. J Allergy Clin Immunol. 2013;132:361e70. doi:10.1016/j.jaci.2013.04.04623777851
   PubMed Web of Science ®Google Scholar
• Chang SH, Reynolds JM, Pappu BP, Chen G, Martinez G, Dong C. Interleukin-17C promotes Th17 cell responses and autoimmune disease via interleukin-17 receptor E. Immunity. 2011;35:611e21. doi:10.1016/j.immuni.2011.09.01021982598
   PubMed Web of Science ®Google Scholar
• Guttman-Yassky E, Krueger JG. IL-17C: A unique epithelial cytokine with potential for targeting across the spectrum of atopic dermatitis and psoriasis. J Invest Dermatol. 2018;138(7):1467–1469. doi:10.1016/j.jid.2018.02.03729941097
   PubMed Web of Science ®Google Scholar
• Vandeghinste N, Klattig J, Jagerschmidt C, et al. Neutralization of IL-17C reduces skin inflammation in mouse models of psoriasis and atopic dermatitis. J Invest Dermatol. 2018;138(7):1555–1563. doi:10.1016/j.jid.2018.01.03629474945
   PubMed Web of Science ®Google Scholar
• Brembilla NC. Senra L. Boehncke W. The IL-17 family of cytokines in psoriasis: IL-17A and beyond. Front Immunol. 2018;9:1682. doi:10.3389/fimmu.2018.0168230127781
   PubMed Web of Science ®Google Scholar
• Megna M, Balato A, Napolitano M, et al. Psoriatic disease treatment nowadays: unmet needs among the “jungle of biologic drugs and small molecules”. Clin Rheumatol. 2018;37:1739–1741. doi:10.1007/s10067-018-4090-629644570
   PubMed Web of Science ®Google Scholar
• Raimondo A, Balato A, Megna M, et al. Limitations of current monoclonal antibodies for plaque-type psoriasis and an outlook for the future. Expert Opin Biol Ther. 2018;18(6):605–607.29788767
   PubMed Web of Science ®Google Scholar
• Talamonti M, Galluzzo M, Bianchi L, Boca AN, Costanzo A, Chimenti S. What happened after the clinical trials: long-term safety and efficacy of ustekinumab in daily clinical practice. Dermatology. 2014;229(4):324–332. doi:10.1159/00036507725402662
   PubMed Web of Science ®Google Scholar
• Talamonti M, D’Adamio S, Bianchi L, Galluzzo M. The role of pharmacogenetics in chronic plaque psoriasis: update of the literature. Mol Diagn Ther. 2017;21(5):467–480. doi:10.1007/s40291-017-0274-z28374122
   PubMed Web of Science ®Google Scholar